501 related articles for article (PubMed ID: 20215531)
21. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
22. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
23. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
24. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
[TBL] [Abstract][Full Text] [Related]
25. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
27. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
Ferrone CR; Levine DA; Tang LH; Allen PJ; Jarnagin W; Brennan MF; Offit K; Robson ME
J Clin Oncol; 2009 Jan; 27(3):433-8. PubMed ID: 19064968
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
29. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
30. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
31. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
32. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
33. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
34. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
[TBL] [Abstract][Full Text] [Related]
35. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
[TBL] [Abstract][Full Text] [Related]
36. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
Andrieu N; Easton DF; Chang-Claude J; Rookus MA; Brohet R; Cardis E; Antoniou AC; Wagner T; Simard J; Evans G; Peock S; Fricker JP; Nogues C; Van't Veer L; Van Leeuwen FE; Goldgar DE
J Clin Oncol; 2006 Jul; 24(21):3361-6. PubMed ID: 16801631
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
[TBL] [Abstract][Full Text] [Related]
38. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
39. The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.
Sundararajan S; Ahmed A; Goodman OB
Clin Adv Hematol Oncol; 2011 Oct; 9(10):748-55. PubMed ID: 22252577
[TBL] [Abstract][Full Text] [Related]
40. Ductal carcinoma in situ in BRCA mutation carriers.
Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]